Global Marketing and Strategy Leader Martha Pease Joins BioSig Board of Directors
September 26 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device
company developing a proprietary biomedical signal processing
platform designed to address an unmet technology need for the
electrophysiology (EP) marketplace, today announced that it
appointed Ms. Martha Pease as an Independent Director.
Ms. Pease brings to the Company over 30 years of recognition and
experience leading organizations in customer centric growth
strategy and creating digital leverage powered by data analytics to
increase shareholder value. Her global perspective, ability to
navigate critical inflection points and direct expertise in scaling
businesses and brands are hallmarks of her career. Ms. Pease began
her career in advertising with DDB and Mobil Oil, shifting to the
IBM Personal Computer account at Lord, Geller, Federico, Einstein
and then moving rapidly up the account management ladder at BBDO as
leader of the Apple Computer account portfolio. Across a range of
executive roles, Ms. Pease has spearheaded major equity building
initiatives for companies including Neutrogena, Domino’s, Lifetime
TV, L’Oreal Paris, Pizza Hut and Lane Bryant. An on-air and online
commentator for CNN, she analyzes the impact of breaking news on
perceptions and leadership. Currently, Ms. Pease serves as a
Partner and Director at BCG (Boston Consulting Group) focused on
growth strategy and digital transformation with an emphasis on the
healthcare sector. Ms. Pease holds a BA, with High Honors, in
English Literature and Film History from Dartmouth College, and is
a graduate of the Harvard Radcliffe Publishing Procedures Course at
Harvard University.
“BioSig Technologies, Inc., led by Chairman and CEO Ken
Londoner, along with the esteemed Board of Directors and the
extraordinary leadership team, are driving their proprietary signal
processing platform to the next level of growth and impact. I’m
honored to join the team as a Board Director and offer my brand
building experience in innovative technology and consumer markets
to help create new value in this exciting healthcare sector of
electrophysiology,” commented Ms. Pease.
“Having been at the forefront of some of the most successful
technology launches at IBM and Apple, Martha brings a unique
perspective to our distinguished Board of Directors. Her expertise
in brand management and building technology demand should be very
advantageous to BioSig at this stage of our growth. We are thrilled
to have Martha on the team and look forward to her contributions,”
stated Kenneth L. Londoner, Founder, Chairman and CEO of BioSig
Technologies, Inc.
Ms. Pease is the latest high-profile addition to BioSig’s Board
of Directors, after investment banker and medtech industry veteran
Samuel E. Navarro and former Chief Medical Officer of Celgene Dr.
Jerome Zeldis, M.D., Ph.D joined the Company’s Board earlier
this year.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP™ System. The
technology has been developed to address an unmet need in a large
and growing market.The Company’s first product, PURE EP™ System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory. The system is indicated for use under the
supervision of licensed healthcare practitioners who are
responsible for interpreting the data. This novel cardiac signal
acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during
electrophysiology procedures in patients with abnormal heart rates
and rhythms. BioSig’s ultimate goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
203-409-5444, x119
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024